- Home
- IMUX vs RSSS Comparison
IMUX vs RSSS Comparison
Compare IMUX & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | RSSS |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 97.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMUX | RSSS |
|---|---|---|
| Price | $0.55 | $2.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | ★ 1.5M | 67.9K |
| Earning Date | 02-14-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $49,325,684.00 |
| Revenue This Year | N/A | $4.92 |
| Revenue Next Year | N/A | $7.09 |
| P/E Ratio | ★ N/A | $73.00 |
| Revenue Growth | N/A | ★ 5.83 |
| 52 Week Low | $0.51 | $2.32 |
| 52 Week High | $1.39 | $4.24 |
Technical Indicators
Market Signals| Indicator | IMUX | RSSS |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 46.77 |
| Support Level | $0.51 | $2.82 |
| Resistance Level | $0.60 | $3.04 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 27.67 | 35.45 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.